[account_shop_links]
Site networks are becoming a more established part of clinical trial planning. As sponsors, CROs, and sites look for greater operational efficiency and faster site and patient recruitment, site networks are playing a larger role in how trials are managed. The bigger question now is not whether site networks matter, but which capabilities sponsors value most and how providers can differentiate themselves as adoption grows.
Site network adoption is becoming standard practice
Site networks are already part of mainstream trial planning, not something sponsors are simply testing. Three out of four sponsors in our research say they are already using site networks in at least some trials, and 92% of respondents say they are Very likely or Somewhat likely to consider using site networks to recruit sites for upcoming trials. These findings suggest the model is becoming a standard part of how sponsors approach site selection and trial execution.
What sponsors value most in a site network
What sponsors seem to value most in a site network is better execution. Nearly one-third of respondents (30%) said, assuming therapeutic expertise / access to patient population is a given, that a Streamlined start-up process from standardized templates, contracts, regulatory documents is the most important site network selection attribute while nearly 60% place it among their top 3 most important selection attributes.
Attempting to solve site-level challenges
Respondents identified a few top pain points in working with sites: Too many competing trials at site, lack of attention/priority (26%), Poor patient recruitment processes/resources (25%), and Delays in contracting, negotiating prices/costs (19%). Site networks may not be able to reduce the number of competing trials but strive to reduce friction in the contracting and patient recruitment processes.
What this means for site network providers
Site networks are becoming a more established part of clinical development. Adoption is strong, the value proposition centers on speed and consistency, and providers can differentiate themselves by understanding the sponsor perspective and responding to it in practical ways.
Sponsors are signaling clear priorities:
- Faster, standardized start-up processes
- Access to qualified sites
- Transparent communication and expectations
Site networks that fail to deliver on these priorities may find it harder to build lasting partnerships as sponsors and CROs continue to strive for faster and more efficient trials. For organizations that want a deeper look at how sponsors and CROs are evaluating site networks, ISR’s Site Networks Market Dynamics report offers a more complete view of the adoption trends, selection criteria, and operational challenges shaping the market. This research can help teams better understand market expectations and align their capabilities with what clients value most.
Primary market research data in this article were powered by the ISR Life Science Panel. Want to contribute to thought leadership pieces and help to make the pharma industry better? Join today.
Learn More Site Networks Market Dynamics
About the Author
Brandon Allison
Marketing Director
Brandon Allison is ISR’s Marketing Director and a versatile contributor across the organization, supporting marketing, sales, and operational efforts since 2021. With more than a decade of experience spanning sales, customer service, and strategic communication, he brings a practical, people centered perspective to ISR’s mission: connecting pharmaceutical service providers with the insights they need to keep drug development moving.
In his role, Brandon works with the analyst team to make ISR’s research easy to understand and even easier to use. Whether he’s shaping content, refining messaging, or helping present complex data in an approachable way, Brandon focuses on giving readers the information they need to make confident decisions. His eye for detail also plays a key role in sharpening ISR’s syndicated reports and other resources that support the industry.
A lifelong musician and songwriter, Brandon approaches his work with an instinct for creativity and pattern recognition. He’s perpetually curious, driven to improve processes, and never satisfied with doing things a certain way simply because “that’s how it’s always been done.” Known as a supportive teammate and thoughtful problem-solver, he’s committed to helping ISR deliver high-quality, actionable intelligence to the pharma services market—one well-crafted message at a time.
